Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

The FDA approved a new Pfizer drug for hair loss in teens.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Stopping gefitinib improved scalp condition in a woman with lung cancer.

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.

The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Topical tofacitinib may help regrow hair in children with alopecia totalis.

Sorafenib can cause a unique skin reaction.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Sorafenib after liver surgery may increase survival for some liver cancer patients.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.

Topical tofacitinib is effective and safe for treating alopecia areata.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.